好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Automated Segmentation of White Matter Hyperintensities on Portable Low-Field Magnetic Resonance Imaging
Cerebrovascular Disease and Interventional Neurology
P9 - Poster Session 9 (11:45 AM-12:45 PM)
13-002
To validate an automated WMH segmentation platform on a large cohort of patients with vascular risk factors.

Portable magnetic resonance imaging (pMRI) is a promising tool for the detection of white matter hyperintensities (WMH) as conventional MRI (cMRI) often poses logistical and financial burdens. Automated segmentation of pMRI may further facilitate detection and characterization of WMH. Here we assess the accuracy of an automated WMH segmentation platform in a cohort of patients with vascular risk factors.

Patients with at least one vascular risk factor were prospectively recruited at an academic medical center chest pain center between December 2021 to July 2024. In a cross-sectional design, participants underwent fluid-attenuated inversion recovery (FLAIR) acquisition on a 0.064 T MRI device (Hyperfine Inc) and medical history questionnaire. Each pMRI scan was processed using WMH-SynthSeg, a machine learning algorithm designed to process sequences of any resolution. Patient cMRIs obtained within 1 year of pMRI were also processed with WMH-SynthSeg as a benchmark to assess volume agreement (n=36). Subsequently, we evaluated the relationship between WMH volume and known risk factors including age, hypertension, hyperlipidemia, atrial fibrillation, and congestive heart failure using Pearson’s correlations and unpaired t-tests.

We found that pMRI and cMRI WMH volumes were strongly correlated (n=36) (r=0.87, p<0.001). To account for the time difference between pMRI and cMRI scans, we adjusted WMH volumes for an established rate of WMH progression, which did not impact the correlations. Among 161 total participants (62.2±12.4 years, 54% male, 26% black), those with atrial fibrillation exhibited greater WMH volumes (mean 12.2±8.8 mL vs 8.8±5.6 mL, p=0.009). Additionally, WMH volume was significantly correlated with age (r=0.52, p<0.001).

Automatic segmentation of WMH from pMRI scans showed significant agreement with conventional imaging. Additionally, greater age and atrial fibrillation were associated with higher WMH volume, reproducing previous findings from cMRI.

Authors/Disclosures
Ian P. Johnson
PRESENTER
Mr. Johnson has nothing to disclose.
Joel Smith, Clinical Researcher Mr. Smith has nothing to disclose.
Emma S. Peasley (Yale School of Medicine) Miss Peasley has nothing to disclose.
Hailey Brigger Ms. Brigger has nothing to disclose.
Alison Champagne Mrs. Champagne has nothing to disclose.
Gordon Sze Gordon Sze has nothing to disclose.
Sam Payabvash Sam Payabvash has nothing to disclose.
Dheeraj D. Lalwani (Yale University School of Medicine, Department of Neurology) Mr. Lalwani has nothing to disclose.
Julia Zabinska Ms. Zabinska has nothing to disclose.
Jua Iglesias Gonzalez (Martinos Center for Biomedical Imaging) Jua Iglesias Gonzalez has nothing to disclose.
Matthew Rosen Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for DeepSpin. Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chipiron. Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Synex Medical. Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Nanalysis. Matthew Rosen has stock in Hyperfine. Matthew Rosen has stock in Q Bio. Matthew Rosen has stock in Vizma Life Sciences. Matthew Rosen has stock in Intact Data Services. The institution of Matthew Rosen has received research support from Imagion. Matthew Rosen has received intellectual property interests from a discovery or technology relating to health care.
Annabel Sorby-Adams (Massachusetts General Hospital and Harvard Medical School) Annabel Sorby-Adams has nothing to disclose.
W. T. Kimberly, MD, PhD (Massachusetts General Hospital) Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrocyte Pharmaceuticals. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acasti Pharma. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Kimberly has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Stryker. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurotherapeutics. Dr. Kimberly has stock in Woolsey Pharmaceuticals. Dr. Kimberly has stock in Acasti Pharma. The institution of Dr. Kimberly has received research support from NIH. The institution of Dr. Kimberly has received research support from Hyperfine, Inc.. The institution of Dr. Kimberly has received research support from Alzheimer's Association. Dr. Kimberly has received intellectual property interests from a discovery or technology relating to health care.
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care) Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.
Adam De Havenon, MD, FAAN (Yale University) Dr. De Havenon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has or had stock in Certus.Dr. De Havenon has or had stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.